Skip to main content
HRMY
NASDAQ Life Sciences

Former CFO Sandip Kapadia Files Intent to Sell Another $1.8 Million in Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$36.41
Mkt Cap
$2.108B
52W Low
$25.52
52W High
$40.87
52W Position info
43% above low
Off High info
11% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

HRMY sits 43% above its 52-week low of $25.52.

Summary

Former CFO Sandip Kapadia plans to sell $1.8 million in Harmony Biosciences stock, continuing a pattern of significant share dispositions since his departure.


Key Events · Ownership and Investor Activity · HRMY

  • Intent to Sell Additional Shares

    Former CFO Sandip Kapadia filed a Form 144 to sell 50,000 shares of common stock, valued at approximately $1.8 million.

  • Continuation of Selling Pattern

    This proposed sale follows previous dispositions by Mr. Kapadia, who has sold 132,606 shares totaling over $4.4 million in the last three months, indicating an ongoing liquidation of his stake.

  • Former Executive's Disposition

    The filer, Sandip Kapadia, is a former officer of Harmony Biosciences, and his continued sales represent a significant reduction in holdings by a key former executive.


Analysis · HRMY · Life Sciences

Former CFO Sandip Kapadia has filed a Form 144 indicating his intent to sell an additional $1.8 million worth of Harmony Biosciences stock. This follows a series of sales totaling over $4.4 million in the past three months, signaling a continued liquidation of his holdings after his departure. This ongoing pattern of sales by a former key executive is a notable event for investors.

How filings like this one have moved

In the 30 days to Sep 21, 2026, 29.2% of the 1543 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HRMY was trading at $36.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $25.52 to $40.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HRMY - Latest Insights

HRMY
Aug 07, 2026, 4:48 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $38.41
Real-time Price: $41.00 info
Change: +$2.59 (+7%) info
Market Cap: $2.447B info
HRMY
Aug 05, 2026, 6:56 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $37.05
Real-time Price: $41.00 info
Change: +$3.95 (+11%) info
Market Cap: $2.447B info
HRMY
Aug 04, 2026, 8:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.75
Real-time Price: $41.00 info
Change: +$4.25 (+12%) info
Market Cap: $2.447B info
HRMY
Aug 04, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $37.25
Real-time Price: $41.00 info
Change: +$3.75 (+10%) info
Market Cap: $2.447B info
HRMY
Jul 20, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $34.10
Real-time Price: $41.00 info
Change: +$6.90 (+20%) info
Market Cap: $2.447B info